Profile data is unavailable for this security.
About the company
Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.
- Revenue in CNY (TTM)172.61m
- Net income in CNY-1.09bn
- Incorporated2017
- Employees581.00
- LocationDizal Jiangsu Pharmaceutical Co LtdNo.199 Liangjing RoadPudong New DistrictSHANGHAI 201203ChinaCHN
- Phone+86 2 161095757
- Fax+86 2 158387361
- Websitehttp://www.dizalpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Cheng Da Co Ltd | 11.18bn | 17.48m | 15.11bn | 3.36k | 760.00 | 0.5182 | -- | 1.35 | 0.013 | 0.013 | 7.34 | 19.07 | 0.2358 | 4.41 | 6.49 | 3,330,121.00 | -0.5366 | 3.59 | -0.7644 | 5.21 | 16.03 | 14.15 | -2.28 | 9.89 | 0.7792 | -- | 0.2834 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
| KPC Pharmaceuticals Inc | 7.65bn | 432.35m | 15.27bn | 5.05k | 35.04 | 2.82 | -- | 2.00 | 0.5757 | 0.5757 | 10.20 | 7.15 | 0.8021 | 2.48 | 2.62 | 1,513,702.00 | 4.63 | 5.42 | 7.76 | 9.13 | 43.12 | 43.68 | 5.77 | 5.70 | 1.46 | 53.93 | 0.1688 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 11.78bn | 843.91m | 15.33bn | 11.61k | 17.88 | 1.21 | -- | 1.30 | 0.6394 | 0.6394 | 8.95 | 9.48 | 0.6069 | 3.08 | 6.61 | 1,014,487.00 | 5.75 | 4.85 | 8.50 | 8.17 | 37.09 | 43.00 | 9.48 | 7.03 | 1.82 | -- | 0.1057 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| Dizal Jiangsu Pharmaceutical Co Ltd | 172.61m | -1.09bn | 16.40bn | 581.00 | -- | 23.54 | -- | 95.00 | -2.67 | -2.67 | 0.422 | 1.68 | 0.1008 | 0.3215 | 6.78 | 297,086.40 | -63.79 | -46.02 | -82.62 | -52.99 | 96.41 | 57.53 | -632.90 | -2,081.54 | 1.74 | -- | 0.4557 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Jiang Zhong Pharmaceutical Co Ltd | 4.30bn | 734.24m | 16.41bn | 4.01k | 22.36 | 3.98 | -- | 3.81 | 1.17 | 1.17 | 6.83 | 6.55 | 0.6698 | 4.34 | 13.62 | 1,071,799.00 | 12.35 | 10.82 | 18.82 | 15.08 | 64.01 | 65.02 | 18.44 | 18.17 | 1.47 | -- | 0.0061 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| Shandong Buchang Pharmaceuticals Co Ltd | 12.37bn | -22.28m | 17.36bn | 8.31k | -- | 1.50 | -- | 1.40 | -0.0202 | -0.0202 | 11.18 | 10.46 | 0.5678 | 1.00 | 9.58 | 1,488,478.00 | -0.9013 | 3.26 | -1.30 | 4.72 | 64.05 | 74.71 | -1.59 | 4.85 | 0.5348 | 2.34 | 0.2522 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
Data as of May 31 2024. Currency figures normalised to Dizal Jiangsu Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
17.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 9.25m | 7.82% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 2.93m | 2.47% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 1.57m | 1.33% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 1.49m | 1.26% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.09m | 0.92% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.05m | 0.88% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 975.11k | 0.82% |
| Golden Eagle Asset Management Co., Ltd.as of 31 Dec 2023 | 709.64k | 0.60% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 612.14k | 0.52% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 595.69k | 0.50% |
More ▼
Data from 31 Dec 2023 - 30 May 2024Source: FactSet Research Systems Inc.
